An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.
Explore this paper's citation graph
Summary
The maximum-tolerated dose (MTD) and the recommended dose of irinotecan and oxaliplatin with a fixed 5-fluorouracil (5-FU)/leucovorin (LV) regimen in patients with metastatic solid tumors is 85/180 mg/m2 or simplified LV5FU.
- Type
- article
- Published
- 2003-03-01
- Cited by
- 108
- References
- 44
- OpenAlex
- https://openalex.org/W2145139896
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:3999139
Keywords
Medicine, Irinotecan, Oxaliplatin, Folinic acid, Regimen
References
- Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.
- Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
- Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
- Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
- Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
- Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
- Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.
- Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.
- Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.
- Folfiri then folfox of folfox then folfiri in metastatic colorectal cancer (MCRC): results of a phase III trial
- A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
- CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR.
- Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.
- Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.
- CPT-11 (irinotecan) in the treatment of colorectal cancer.
- Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers
- Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.
- Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data.
- Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy.
- Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).
Cited by
- Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer
- FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
- Multiple-target Chemotherapy (Lv-modulated 5-FU Bolus and Continuous Infusion, Oxaliplatin, CPT-11) in Advanced 5-Fu-refractory Colorectal Cancer: Mtd Definition and Efficacy Evaluation. A Phase I-II Study
- Development and evaluation of an oral fixed–dose triple combination dosage form for artesunate, dapsone and proguanil
- A Pilot Phase ii Study of Chemotherapy with Oxaliplatin, Folinic acid, 5-Fluorouracil and Irinotecan in Metastatic Gastric Cancer
- Identifying biomarkers of response to modified folfirinox regimens using patient derived xenograft mouse models of pancreatic ductal adenocarcinoma
- Outcomes with FOLFIRINOX for Borderline Resectable and Locally Unresectable Pancreatic Cancer
- New Advances in the Treatment of Metastatic Pancreatic Cancer
- Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies
- Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
- Strategia oncochirurgica di gestione delle metastasi epatiche di origine colorettale
- A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer
- miRNAs for the Detection of MultiDrug Resistance: Overview and Perspectives
- The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer
- Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer
- Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study
- Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer
- A Phase I–II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas
- FOLFIRINOX for the treatment of colorectal cancer: latest evidence from clinical trials
- Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases
Related papers
- Oxaliplatin plus fluoriouracil and folinic acid combination chemotherapy in the treatment of colorectal carcinoma
- Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
- Новые возможности терапии диссеминированного колоректального рака
- Oxaliplatin for the treatment of advanced colorectal cancer: future directions.
- Folinic acid does improve 5-fluorouracil activity in vivo. Results of a phase III study comparing 5-fluorouracil to 5-fluorouracil and folinic acid in advanced colon cancer patients.
- 716 Oxaliplatin with high-dose folinic acid and 5-fluorouracil 48 H infusion in pretreated metastatic colorectal cancer (CRC)
- Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer.
- Oxaliplatin: in operable colorectal cancer.
- Cost-effectiveness analysis of irinotecan plus fluorouracil/folinic acid compared with fluorouracil/folinic acid alone as first-line treatment for advanced colorectal cancer
- Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude mice